Results 81 to 90 of about 337,315 (208)

A minimally invasive abdominal and left thoracic approach as a palliative treatment for adenocarcinoma of the esophagogastric junction with severe stenosis : A case report [PDF]

open access: yes, 2020
We report a novel technique for combined laparoscopy and thoracoscopy for far-advanced adenocarcinoma of the esophagogastric junction (AEG). A 56-year-old man presented with far-advanced AEG, and an esophagogastroduodenoscopy revealed a type 2 lesion ...
Okamura, Keisuke   +23 more
core   +1 more source

Application of preoperative endoscopic ultrasonography-guided carbon nanoparticle tattooing combined with titanium clip labeling in esophagogastric junction adenocarcinoma

open access: yesThe Turkish Journal of Gastroenterology, 2019
Cite this article as: Lin L, Wang M, Hong J, Yang S, Wang Y. Application of preoperative endoscopic ultrasonography-guided carbon nanoparticle tattooing combined with titanium clip labeling in esophagogastric junction adenocarcinoma. Turk J Gastroenterol
Lan Lin   +4 more
doaj   +1 more source

Revised_supplementary_Materials – Supplemental material for Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis

open access: yes, 2019
Supplemental material, Revised_supplementary_Materials for Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis by Ji Cheng, Ming Cai, Xiaoming Shuai, Jinbo Gao, Guobin Wang and Kaixiong Tao ...
Xiaoming Shuai (2142463)   +5 more
core   +1 more source

High-resolution manometry in the diagnosis of oesophageal motility disorders

open access: yesМедицинский совет, 2018
Esophageal high-resolution manometry is a modern method of diagnosis performed worldwide as the gold standard for assessing esophageal motility. The Chicago classification is applied to interpret the manometric findings.
E. V. Barkalova   +2 more
doaj   +1 more source

Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer

open access: yesBMC Cancer
Background Capecitabine + oxaliplatin (CapeOX) + zolbetuximab and 5-FU + oxaliplatin (mFOLFOX6) + zolbetuximab are recommended as first-line treatments for chemotherapy-naïve patients with HER2-negative, CLDN18.2-positive advanced gastric or ...
Satoshi Yuki   +11 more
doaj   +1 more source

Esophagogastric Junction Outflow Obstruction After Corrosive Esophageal Injury

open access: yes
Background: This study evaluated symptomatic patients after corrosive esophageal injury who had normal follow-up endoscopy, with a focus on patients with esophagogastric junction outflow obstruction (EGJOO) identified on high-resolution manometry.
Dharshan Gowda H. S   +2 more
core   +1 more source

Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia

open access: yes, 2002
OBJECTIVES: Intestinal metaplasia in Barrett’s esophagus predisposes to esophageal adenocarcinoma. Intestinal metaplasia of the cardia is a common finding in persons without cancer. Many adenocarcinomas of the esophagogastric junction are large enough to
Cameron, Alan J   +2 more
core   +1 more source

Esophageal and Esophagogastric Junction Cancers, Version 1.2015 [PDF]

open access: yes, 2015
Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric ...
Charles S. Fuchs   +74 more
core   +1 more source

Management of metastatic esophagogastric junction adenocarcinoma

open access: yes, 2018
The prognosis of metastatic disease of esophagogastric junction adenocarcinoma remains poor, despite using a variety of regimens using cytotoxic agents.
Imamura, Yu   +3 more
core  

Long-Term Results with Surgery Alone and Multimodal Treatments

open access: yes, 2017
Esophagogastric junction (EGJ) adenocarcinoma survival improved recently, thanks to the use of multimodal treatments. Survival with surgery alone is instead still poor in all locally advanced and node-positive patients. Recurrence is still the main cause
Weindelmayer, Jacopo   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy